Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The First-in-Human, Single-Center, Randomized, Double-Blind, Placebo-Controlled，Single- and Multiple- Ascending Dose Study to Evaluate the Safety and Tolerability of WS016 in Healthy Chinese Volunteers

NCT06281470 is registered in ClinicalTrials.gov with Waterstone Pharmaceutical (Wuhan) Co., LTD. as lead sponsor.

NCT NCT06281470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06281470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The First-in-Human, Single-Center, Randomized, Double-Blind, Placebo-Controlled，Single- and Multiple- Ascending Dose Study to Evaluate the Safety and Tolerability of WS016 in Healthy Chinese Volunteers
Lead sponsor
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase
Phase 1
Overall status
Completed
Start date
February 13, 2023
Completion date
June 15, 2023
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia